📌 Key Takeaways
- Topic: Silica in Cosmetics: Functions, Types and Safety
- Keywords: silica for UV adhesive
- Published: 2026-11-20 06:00:10
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica for Solar Crucible: Purity Standards and Supply Considerations
- Talc Powder vs Silica: Differences and Which Filler to Choose
- 2. Effect of the Physicochemical Properties
- Silica Supplier in China: How to Find, Verify and Work with Chinese Producers
- 59. Ritger P.L., Peppas N.A. An effortless equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release. 1987;5:23-36. doi: 10.1016/0168-3659(87)90034-4. [ DOI ] [ PubMed ] [ Google Scholar ]
- What Is Silane Treated Silica? How Silane Modification Improves Dispersion and Performance
- Magnetic particles were synthesized with an iron-containing coating. The model drugs were safranin O and hydrocortisone. The particles were functionalized with a bulky azo derivative to act as a gatekeeper and stop early leakage of the drug. In vitro release models have demonstrated that most of the drug is released only in the colon, as desired. This is owing to the reductive environment in the colon (the presence of the azoreductase enzyme), where the enzymatic degradation of the azo bond resulted in controlled release. In addition, in vivo pharmacokinetic studies were conducted in a rat model of induced colitis to test the effect of the magnetic field during therapy. The findings boosted when the rats wore a magnetic belt, which extended the retention time of the particles in the desired areas [ 75 ]. Zhang et al. presented a study in which magnetic silica nanoparticles (filled with sulforaphane) were developed for the treatment of myocardial infarction [ 38 ]. In mouse models, effective accumulation was observed in the infarcted zone after the application of an external magnetic field [ 33, 75 ]. These results show the potential of using magnetic particles with magnetic field guidance [ 33 ]. Radhakrishnan et al. developed a drug delivery system (DDS) loaded with carboplatin for targeted lung cancer therapy [ 63 ]. The DDS was core-shell mesoporous silica functionalized with folic acid. Initially, the drug loading capability of the functionalized carrier was more than twice as high per surface unit compared to the non-functionalized carrier due to the anchored -NH 2 groups. The drug release was sustained but limited (up to 36%) in the case of the functionalized particle, similarly to previous cases. This is most likely owing to the stronger interactions between the amine groups and the carboplatin. The amino-functionalized particles were further functionalized with folic acid to increase cellular uptake of the particles, demonstrating the potential of folic acid-targeted therapy [ 63, 65, 76 ]. Cancer cells typically overexpress folate receptors, resulting in folate-mediated internalization that preferentially targets these cells [ 63, 76 ]. This was demonstrated in a drug-mediated cytotoxicity analysis where amino- and folate-functionalized particles were evaluated and compared. Much greater cytotoxicity was observed in cells overexpressing folate receptors [ 63 ]. Similar research was carried out by Shirani et al., where folic acid functionalized MSNs were loaded with gemcitabine as a model drug, to investigate its potential in cancer treatment, while actively targeting cancer cells [ 70 ]. Outcomes have shown that higher cellular uptake (HeLa and K562 cells) was observed in the case of the functionalized particles, compared with the non-functionalized carriers [ 70 ]. Jafarpour et al. demonstrated the importance of functionalizing the carriers to accomplish targeted therapy utilizing methotrexate as a model drug [ 76 ]. The particles were grafted with a copolymer to act as a pH-responsive gatekeeper and folic acid to actively target cancer cells [ 76 ]. Ortiz et al. similarly designed a pH-responsive DDS, loaded with the anticancer drug doxorubicin [ 11 ]. The particles were functionalized with transferrin through a pH-sensitive linker as a gatekeeper, controlling the release kinetics and preventing early leakage of the drug [ 11 ]. An interesting breast cancer therapy was published by Mal et al. using doxorubicin as API and mesoporous silica as a carrier [ 65 ]. The amine-functionalized MSNs were PEGylated and then conjugated with folic acid or hyaluronic acid. It was also published that coating the nanoparticles with polydopamine (PDA) and polyethylene glycol (PEG) brings about prolonged doxorubicin release from MSNs [ 77 ]. These conjugates enabled ligand-mediated targeted drug delivery [ 65 ]. Researchers have developed a successful DDS that targets cancer cells, thus staying away from the side effects associated with doxorubicin in conventional cancer therapy. This is important because in vitro cytotoxicity studies have shown that the free drug has higher cytotoxicity than the nanocarriers [ 65 ]. Shahbaz et al. developed a redox-responsive silica nanocarrier loaded with paclitaxel to target breast cancer cells [ 67 ]. The amine-functionalized silica core was coated with disulfide-functionalized non-porous silica shell. Then the core-shell carriers were further coated with polyethylene glycol via disulfide linkages. In vitro drug release assay verified the correlation between the redox potential of the environment and the release kinetics. This is an important finding, as it has been revealed that cancer cells possess a higher redox ability than healthy cells. This provides controlled paclitaxel release for targeted therapy. According to cell uptake and cell viability assays, this DDS is noticeably more effective than free paclitaxel, making this nanocarrier an exciting prospect [ 67 ]. These illustrations highlight the importance of surface functionalization and employing stimuli-responsive gatekeepers to attain productive targeted therapy.
- Cabot Cab-O-Sil: Product Range, Key Grades and Alternatives
- 3. Farzan M., Roth R., Schoelkopf J., Huwyler J., Puchkov M. The processes behind drug loading and release in porous drug delivery systems. Eur. J. Pharm. Biopharm. 2023;189:133-151. doi: 10.1016/j.ejpb.2023.05.019. [ DOI ] [ PubMed ] [ Google Scholar ]
Foundry Silica Sand: AFS Grain Fineness, Specifications and Uses
What is silica (SiO₂)?
fumed silica market
What is the difference between fumed silica and precipitated silica?
nano silica price Things to Be Aware of
What drives silica raw material prices?
silica OEM The skin is our largest organ, which consists of three layers: the epidermis, dermis, and hypodermis. Owing to its big surface zone, it also serves as an essential gateway for drug administration [ 25 ], which is fitting for both local (dermal) or systemic (transdermal) therapy [ 25, 56 ]. In spite of the popularity of this administration route, it is a challenge to get the API into deeper layers of the skin. The outermost layer of the epidermis, the stratum corneum, is the biggest hurdle to molecular penetration [ 25, 56 ]. However, the molecules must be absorbed through the capillaries of the dermis to achieve a systemic impact, which can be facilitated employing nanocarriers [ 56 ]. In addition, sweat glands or hair follicles can be effective alternative routes for the molecules to enter the deeper layers of the skin [ 25, 56 ]. In summary, it can be called as the transappendageal route. Among physicochemical properties, particle size is one of the most vital factors influencing absorption. Particles in the range between 200 and 300 nm are suitable for local treatment of the skin in diseases such as atopic dermatitis [ 25 ] since particles larger than 75 nm do not pass through the stratum corneum [ 25 ]. Smaller particles (approximately 50 nm) are suitable for systemic treatment [ 25 ], and on the whole, it can be said that nanoparticles with a diameter smaller than 25 nm can penetrate the skin most effectively, so they can be used for transdermal drug administration with an appropriate formulation [ 56 ]. By controlling the size of the nanocarrier, they penetrate to different depths in the skin. From the element of surface characteristics, cationic amino-functionalized MSNs show more efficient penetration into deeper layers of the skin than the particles with anionic surfaces of the same size [ 25 ]. The use of MSNs as a drug carrier may improve aqueous solubility, stability, and skin penetration of the drug [ 61 ]. In a research, gels containing MSN were prepared by employing distilled water to form the base, adding the gelling agent (Poloxamer 407), and adding HPMC to enhance the viscosity [ 83 ]. In another publication, MSN containing oleogels were prepared with sunflower oil and the addition of colloidal silicon dioxide as a gelling agent [ 61 ]. According to in vitro experiments, the gel matrix also affected the drug release kinetics [ 61, 83 ]. Slower drug release was observed in the case of gels containing loaded MSNs, compared to the free carriers, and the outcomes demonstrated close to zero-order release kinetics [ 61 ]. According to in vitro biocompatibility studies, this gel complex did not show any evidence of cytotoxicity on dermal fibroblast cells. Moreover, according to in vivo dermal safety studies, it has been proven that this preparation does not cause skin irritation during application, and so this formulation can be considered a safe product [ 61 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.